Notice of Intent to Sole Source Lease of Avatar Odyssey Tender

• Country: USA
• Summary: Notice of Intent to Sole Source Lease of Avatar Odyssey Instruments Xcell Biosciences
• UST Ref No: 138867993
• Deadline: 10 Apr 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: 26-004627
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Notice of Intent to Sole Source - Lease of Avatar™ Odyssey Instruments (Xcell Biosciences)
  NAICS Code: 532490 - Other Commercial and Industrial Machinery and Equipment Rental and Leasing
  Product Service Code (PSC):W066 - Lease or Rental of Equipment - Laboratory Equipment
  Description:
  This is a Notice of Intent, not a request for quotations. A solicitation will not be issued, and quotations will not be requested. This notice is for informational purposes only.
  The Department of Health and Human Services (HHS), National Institutes of Health (NIH), Clinical Center (CC), Office of Purchasing and Contracts, on behalf of the Center for Cellular Engineering (CCE), intends to award a firm-fixed-price contract on a sole source basis to:
  Xcell Biosciences, Inc.
  455 Mission Bay Blvd Suite 124
  San Francisco, California 94158-2159
  Requirement:
  The purpose of this acquisition is to lease four (4) Avatar™ Odyssey instruments for a period of six (6) months to support process development activities within the CCE laboratories located at the NIH Clinical Center, Bethesda, Maryland.
  These instruments enable precise control of cellular microenvironment conditions, including oxygen tension (hypoxia to normoxia), pressure, and temperature, which are critical for evaluating and optimizing cell therapy manufacturing processes.
  The Center for Cellular Engineering develops and manufactures investigational cell-based therapies for patients with limited or no remaining standard treatment options, in compliance with Current Good Manufacturing Practice (cGMP) requirements (21 CFR Parts 210, 211, 600, and 1271).
  Although the instruments are designated for research use only and will not be used for clinical manufacturing, they are essential for generating data that will inform process optimization, improve cell phenotype and function, and support future acquisition of GMP-compliant systems.
  Authority:
  FAR 13.106-1(b)(1) - Soliciting from a single sourc...
• Documents:

 Tender Notice